scholarly journals Chronic Subcutaneous Infusion Therapy with Apomorphine in Advanced Parkinson's Disease Compared to Conventional Therapy: A Real Life Study of Non Motor Effect

2011 ◽  
Vol 1 (2) ◽  
pp. 197-203 ◽  
Author(s):  
Pablo Martinez-Martin ◽  
Prashanth Reddy ◽  
Angelo Antonini ◽  
Tove Henriksen ◽  
Regina Katzenschlager ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Conventional Therapy ◽  
Real Life ◽  
Infusion Therapy ◽  
Advanced Parkinson’S Disease ◽  
Subcutaneous Infusion ◽  
Life Study ◽  
Motor Effect ◽  
Real Life Study

IncobotulinumtoxinA to treat sialorrhea in Parkinson's disease: a real-life study

2020 ◽  
Vol 79 ◽  
pp. e69-e70
Author(s):  
B. Bergmans ◽  
V. Schotte ◽  
N. Sys ◽  
E. Van Massenhove ◽  
M. Van Zandijcke
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Real Life ◽  
Life Study ◽  
Real Life Study

Beyond Motor Symptoms – Impact of Continuous Dopaminergic Stimulation on Non-motor and Social Aspects of Advanced Parkinson’s Disease

2012 ◽  
Vol 7 ((Suppl.1)) ◽  
pp. 17
Author(s):  
Barbara Pickut ◽  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Infusion Therapy ◽  
Motor Symptoms ◽  
Advanced Parkinson’S Disease ◽  
Continuous Dopaminergic Stimulation ◽  
Anxiety Depression ◽  
Non Motor Symptoms ◽  
Dopaminergic Stimulation

Two patient cases are presented here that illustrate the benefits of continuous dopaminergic stimulation on the non-motor symptoms of Parkinson’s disease. In both cases, levodopa/carbidopa intestinal gel infusion therapy led to improvements in anxiety, depression, concentration, urge incontinence, sexual function, sleep, vivid dreams and rapid eye movement sleep behaviour disorder, pain, sweating and feelings of self-assuredness. Such improvements have an impact on patients’ quality of life and can help their social functioning.

Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience

2015 ◽  
Vol 74 (5-6) ◽  
pp. 227-236 ◽  
Author(s):  
Saeed Bohlega ◽  
Hussam Abou Al-Shaar ◽  
Thamer Alkhairallah ◽  
Fahad Al-Ajlan ◽  
Nael Hasan ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Middle Eastern ◽  
Infusion Therapy ◽  
Advanced Parkinson’S Disease

scholarly journals Long-term effect of apomorphine infusion in advanced Parkinson’s disease: a real-life study

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Bruna Meira ◽  
Bertrand Degos ◽  
Elise Corsetti ◽  
Mohamed Doulazmi ◽  
Emeline Berthelot ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Real Life ◽  
Routine Care ◽  
Motor Fluctuations ◽  
Psychological Status ◽  
Long Term Effects ◽  
Good Tolerability ◽  
Advanced Parkinson’S Disease

AbstractLong-term effects of continuous subcutaneous apomorphine infusion (CSAI) on health-related quality of life (HRQoL) and predictors of CSAI discontinuation are poorly known. Data from consecutive advanced Parkinson’s disease patients treated in routine care were retrospectively collected over 24 months after CSAI initiation, with a focus on the 39-item Parkinson’s disease questionnaire (PDQ-39). We determined predictors of CSAI discontinuation and HRQoL improvement using multiple regression analysis. Of the 110 subjects evaluated over a 2-year period, 35% discontinued CSAI. Of those who continued treatment, HRQoL remained stable with a sustained reduction in motor fluctuations. The observed effect on dyskinesias was mild and transient. Of note, patients with preexisting impulse control disorders showed an overall good tolerability. PDQ-39 was the only baseline predictor of HRQoL improvement after 2 years of treatment. The presence of dyskinesias, poorer psychological status, shorter disease duration, male sex, and worse OFF state were predictors of discontinuation. Best candidates for CSAI are patients with: (i) poor baseline HRQoL and (ii) marked motor fluctuations.

Sign in / Sign up

Export Citation Format

Share Document